Policy and treatment terms
Reading the October peptide policy before choosing care
Read the October documents beside the terms you saved, with a separate question for every claim.
Start with the date attached to the claim
This guide separates the policy document, the corporate announcement and the older care review. Read what each establishes before deciding whether its statements answer your question about a particular offer.
As checked October 29, the Federal Register notice remained unpublished, scheduled for October 30. It describes a nonbinding draft interim policy while the 503A bulks list undergoes rulemaking; comments are invited until two weeks after publication. HHS may reconsider the policy, wholly or partly, for safety signals or product-quality problems. Scheduled publication is not an established treatment launch or a final bulks-list decision. We do not assign an effective date from that schedule. [2]
Use the date above when quoting this account. A later change in the official record would require a separate update.
Read the entry with its conditions
October 29: The draft HHS policy describes conditional 503A compounding discretion for specified forms and routes, not 503B access or product approval. For each peptide, discretion lasts until a final rule decides 503A-list inclusion or exclusion. [1] [2]
Read every row with all ten conditions. The list is an index to the document, not our finding that any pharmacy or preparation qualifies.
Form and route
TB-500: fragment, not full-length thymosin beta-4. BPC-157: no intravenous entry.
Scroll horizontally to read both columns.
| Form | Route |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, topical |
| Epitalon acetate | Subcutaneous, intramuscular; intermittent courses |
| KPV acetate | Topical, oral |
| MOTS-c acetate | Subcutaneous, intramuscular |
| Semax free base | Intranasal |
| TB-500 acetate | Subcutaneous, intramuscular |
Ten conditions in the document
- Appendix A listing.
- Appendix B identity and routes.
- FDA-registered bulk source; valid characterization and testing certificate of analysis (COA), meeting Appendix B criteria.
- Original manufacturer: FDA registration, bulk CGMP, FD&C compliance; site on COA. Registered intermediaries document manufacturer and COA validation.
- Report products, serious events irrespective causation, and quality issues to FDA and origin/destination states; patient-label reporting instructions.
- Label: “This is a compounded drug product. Not for resale.”
- Only one active ingredient, from Appendix A.
- Document adequate human oral bioavailability for the specific dispensed formulation.
- Co-packaged or drug-containing delivery devices: only FDA 510(k)-cleared syringes.
- Other applicable FD&C requirements, including sanitary conditions and patient-specific prescriptions.
Name the subject of each assurance
FDA does not approve compounded drugs or check their safety, effectiveness and quality before marketing. Poor compounding can cause contamination or too much or too little active ingredient, with serious injury or death possible. Qualifying finished 503A compounded drugs are exempt from current good manufacturing practice (CGMP); 503B outsourcing products are subject to it. State pharmacy boards generally handle day-to-day oversight of non-outsourcing pharmacies; FDA can inspect them and primarily oversees outsourcing facilities. Online customers may not know which compounder produced their medicine. [4]
If an offer names different organizations for the consultation, preparation and dispensing, ask who answers for each part. Treat this as a question, not a conclusion about anyone's compliance. [4]
Keep the announcement beside the review
Hims & Hers' October 29 corporate announcement previews Peptides+ and invites a waitlist. It plans Sermorelin, Glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 when allowable. The proposed menu is not all peptides. This is a corporate plan, not verification that Peptides+ is available through the Hers weight-loss program reviewed here. We have not verified ordering or availability. [3]
The announcement contains forward-looking statements, including uncertainty about launch timing and availability. Its description of independent providers, licensed pharmacies and ongoing support is the company's account of its planned service; this publication has not independently qualified those participants or tested that support. [3]
The earlier Hers review concerns its recorded weight-loss offer. Its prices, membership details and cancellation analysis are not estimates for Peptides+. [3]
Ask for terms that answer your decision
For a hypothetical consultation offer, ask what the first payment buys, whether further charges recur, and what happens if the expected next step does not occur. A consultation fee and a cancellation rule answer different questions. This example describes no actual provider's terms.
Ask for missing terms before making the commitment they concern. Keep the response with the offer's name and date; do not borrow terms from another program.
Questions from the reading room
Does the new note change the older review's price?
No. This is a separate document update. The earlier review retains its recorded prices and evidence date; obtain current terms for the offer you are considering.
Does a waitlist confirm that I can order?
No. The announcement invites a waitlist; our review has not verified ordering, launch timing or access through the Hers program. [3]
The Comparison Desk’s reading
Use this account to distinguish a policy condition, a company plan and a recorded care offer. None of our comparisons substitutes for a current answer about the specific service you are considering.
Policy sources
- HHS policyHHS · Checked 2026-10-29
- Public-inspection noticeFederal Register · Checked 2026-10-29
- Peptides+ announcementHims & Hers · Checked 2026-10-29
- Compounding questionsFDA · Checked 2026-10-29